FOXO1 and neoplasm: In our current study, entinostat monotherapy had no effect on tumor growth in 2 ARMS models, which is consistent with prior published observations that PAX3::FOXO1 is to a degree dispensable for tumor maintenance until PAX3::FOXO1 expression goes to absolute zero (i.e., as seen comparing efficient RNA interference studies vs CRISPR)4,19,20 (depmap.org).